Scholars propose changes to patent disclosures under the Biologics Price Competition and Innovation Act. Biologics—drugs made from organic materials, such as vaccines—are thought to be an important factor driving high drug prices. In the United States, biologics make up over half of prescription medicine spending while accounting for only approximately 3 percent of all prescriptions.
Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPP Plan to initiate Phase 2 study of DISC-3405 in polycythemia vera (PV) in H1 2025 Expect data readouts for DISC-0974 program in H2 2025, including
M K Rajashekaran 16 March 2025, 08:14 AM IST With the expiry of patents for several essential medicines, the prices of key drugs, including those for diabetes, asthma, and schizophrenia, are expected to drop significantly as cheaper generic alternatives enter the market. Representational image. Thrissur: The prices of several essential medicines in India are set
Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approval pathway; on track to initiate APOLLO post-marketing confirmatory trial by mid-2025 Positive update from Phase 1b trial of DISC-0974 in patients with anemia of myelofibrosis (MF) presented at ASH 2024; initial data from ongoing Phase 2 expected in H2 2025